<- All drugs

Petrelintide

MARKETED

long-acting amylin analogue (once-weekly s.c.; mono-agonist)

graded findings

effect domains

Evidence spread

High evidence 0Moderate evidence 0Low evidence 1Very low evidence 4

Petrelintide is shown as a marketed evidence record where applicable. Findings describe observed research and regulatory records; they do not provide treatment advice.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Petrelintide MARKETED

Weight change Decrease

Very low evidence

Phase 1b: 6-week MAD gave ~5.3% and 5.1% weight loss at 0.6/1.2 mg weekly; 16-week MAD up to 8.6% mean vs 1.7% placebo, mild GI events. Phase 2b ZUPREME-1 (42 wk,...

Zealand Pharma phase 1b topline (GlobeNewswire June 2024); ZUPREME-1 phase 2b topline (Ze... Source

Full findingPhase 1b: 6-week MAD gave ~5.3% and 5.1% weight loss at 0.6/1.2 mg weekly; 16-week MAD up to 8.6% mean vs 1.7% placebo, mild GI events. Phase 2b ZUPREME-1 (42 wk, obesity/overweight without T2D) met its primary endpoint with up to 10.7% mean weight loss vs 1.7% placebo and 'placebo-like' GI tolerability.

Populationphase 1b MAD: healthy/overweight, 6 and 16 wk; ZUPREME-1: adults obesity/overweight without T2D, 42 wk

Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)

Scope limitsMechanism: selective long-acting amylin receptor analogue, monotherapy (no GLP-1 component); positioned as GLP-1-comparable weight loss with improved GI tolerability and lean-mass preservation. Partnered with Roche 2025. ZUPREME-2 (T2D) from April 2025; phase 3 planned H2 2026. Also studied in combination with Roche's GLP-1/GIP dual CT-388. Topline via company press/registry, not peer-reviewed.

Comparatorsplacebo

Petrelintide MARKETED

Weight change Decrease

Very low evidence

Phase 1b MAD: dose-dependent weight loss over 16 weekly doses

Zealand Pharma topline press release, 20 Jun 2024 Source

PopulationOverweight/obese, median BMI 29, median age 49 (n=48), phase 1b MAD, 16 wk, RCT placebo-controlled

Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)

Scope limitsno outcome data yet (ongoing); small sample (N~48)

Comparatorsplacebo

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Petrelintide MARKETED

Body composition Not directional

Very low evidence

Positioned for high-quality weight loss with lean-mass preservation (company claim)

Zealand Pharma press release, 20 Jun 2024 Source

PopulationCompany positioning / preclinical

Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)

Scope limitsAspirational claim, not yet quantified in humans

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Petrelintide MARKETED

Pharmacology and mechanism Not directional

Low evidence

Long-acting amylin analogue / dual amylin-calcitonin receptor agonist (DACRA); used as reference scaffold for next-gen DACRA optimisation

Zong L et al. J Med Chem 2025;68:14907-14918 Source

PopulationMedicinal-chemistry / SAR (in-vitro + in-vivo)

Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)

Scope limitsPaper characterises petrelintide's agonism as 'insufficient vs natural agonists' (third-party framing)

ComparatorsBGM1812; natural amylin/calcitonin

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.

Petrelintide MARKETED

Gastrointestinal tolerability No change

Very low evidence

Reported safe and well tolerated at all dose levels (company)

Zealand Pharma topline press release, 20 Jun 2024 Source

PopulationPhase 1b MAD (n=48), 16 wk

Fundingindustry - Zealand / Roche (trial sponsor; inferred from registration trial)

Scope limitsno outcome data yet (ongoing); small sample (N~48)

Comparatorsplacebo